Reporter brief
A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis® Plus Sirolimus Versus Lucentis® Plus Placebo in Patients With Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
What happened
Trial registry update: TERMINATED. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No efficacy results are reported, so the actual effect of rapamycin addition on vision or disease progression cannot be determined from this source
- Sample size is unstated, limiting assessment of statistical power and reliability of any results
- As a phase 2 trial, findings would require confirmation in adequately powered phase 3 trials before clinical significance can be established
Study design and sample
Rct; Human.
Patients with sub-foveal choroidal neovascularization secondary to age-related macular degeneration
- Design
- Rct
- Sample
- —
- Journal
- Santen Inc.
- Published
- Jan 10, 2013
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.